Karyotypes, many known valuable fusion genes in AML, and aberrant expression of several molecules, such as mutations in FLT3, C-Kit, NPM1, WT1, and CEBPA genes, are involved in diagnoses and prognosis of patients with AML. Here, FLT3 is linked to acute myeloid leukemia.